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al, 1970). Nowadays,
99mTc-DTPA is a well-known agent for
evaluation of renal function. It is cleared rapidly and efﬁciently
from the circulation by glomerular ﬁltration. This might explain,
for liposomes, the unusual, rapid accumulation of activity in the
tumours. In our opinion, the authors should have performed,
and shown – at least in some patients – a control
99mTc-DTPA
scan, to rule out that the liposome scan represents free
99mTc-
DTPA instead of radiolabelled Caelyx.
A better approach to label Caelyx would be the labelling with
indium-111-oxine (
111In-oxine). This easy method will yieldradio-
labelled liposomes with good radiochemical yield (480%) and
good in vivo stability (Laverman et al, 2001). An additional advan-
tage is the longer physical half-life of
111In, which enables the
acquisition of delayed images and thus better visualization of the
tumours (Harrington et al, 2001).
In summary, scintigraphic techniques are very helpful in inves-
tigating the in vivo distribution of (new) pharmaceuticals, but
should only be performed using well-established labelling techni-
ques and quality control methods. The results presented by
Koukourakis et al (1999, 2000a,b) should therefore be interpreted
with caution.
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Sir
In these previous studies we provided a simple method to label
Caelyx by incubation of 5 mg of the ready-to-use solution with
20 mCi of
99mTc-DTPA. Instant thin layer chromatography (ITLC)
suggested an 80% labelling (Koukourakis et al, 1999), which is also
a result found by Dr Laverman and colleagues. As additional more
sophisticated analysis, performed by the later research group, failed
to conﬁrm this ﬁnding, it was suggested that the tumour and body
imaging obtained in our studies is rather a result of
99mTc-DTPA
and not of labelled liposomes.
99mTc-DTPA is currently used in the evaluation of renal func-
tion, and as well noted by Dr Laverman, this is rapidly cleared
from the kidneys. Two hours following injection, the imaging qual-
ity of kidneys is really poor.
99mTc-DTPA can give good images of
gliomas, probably as a result of the high tumour vascularization or
even of the disrupted blood–brain barrier, which allows a net
contrast between normal and abnormal brain. However, imaging
of other tumours with
99mTc-DTPA is questionable.
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technique labels Caelyx indeed, comes from the clinical practice.
The patterns and quality of imaging using
99mTc-DTPA-Caelyx
has been assessed in more than 30 non-small cell lung cancer
patients comparatively with
99mTc-sestamibi (Koukourakis et al,
1997), while in ﬁve of them imaging with simple
99mTc-DTPA
was also performed at 2 h post-injection. The patterns of normal
tissue imaging using the three radio-pharmaceuticals was entirely
different. The quality of tumour images obtained with sestamibi
and labelled-Caelyx was very good, while in some cases liposomal
imaging was even better. Tumour imaging with
99mTc-DTPA was
of unacceptably poor quality, and rather absent in 3 out of 5 cases.
Similar comparison of the three imaging procedures in patients
with head and neck cancer showed an excellent imaging using
labelled-Caelyx and
99mTc-sestamibi, while using
99mTc-DTPA the
imaging was questionable especially at 2 h post-injection (Figure
1). The superiority of liposomal imaging over sestamibi was
conﬁrmed in more than 10 glioma patients. Indeed, lesions of
some mm in dimensions were perfectly scanned using
99mTc-
DTPA-Caelyx (Koukourakis et al, 2000a), which is rarely seen with
sestamibi.
We, therefore, have to cope with a discrepancy between the clin-
ical imaging and the 1% labelling suggested by Dr Laverman.
99mTc-DTPA is a hydrophilic compound and, as well stressed by
Dr Laverman and colleagues, it is difﬁcult to explain how a hydro-
philic radiotracer can pass through the lipid layer and become
entrapped in the liposomes. There are two possibilities: (a) our
labelling procedure is not efﬁcient and
99mTc-DTPA scanning is
the cheapest, still the best, imaging procedure for tumours (which
is not true according to ours and the general experience); (b)
99mTc-DTPA labels liposomes without passing through the lipid
layer. Caelyx is a pegylated liposome with a water soluble polyethy-
len-glycol coat.
99mTc-DTPA could be entrapped in this layer and
label liposomes without necessitating internalization. The radio-
chemical elaboration of labelled-PEG-liposomes on Sephadex
performed by Dr Laverman could well lead to
99mTc-DTPA disso-
ciation from the PEG-coat, which explains the poor labelling
efﬁciency found.
Simple labelling procedures of liposomal drugs will become of
great value within the following years, when multiple liposomal
agents will be available. The technique described by Laverman et
al (2001) is as simple as ours, while the Indium-oxine labelling
allows a better monitoring of the liposome kinetics for at least 3
days after administration. We will certainly incorporate this in
current and future projects.
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Figure 1 Comparison of images obtained from a patient with a large
naso/parapharyngeal tumoural mass (white box marked on ﬁgures) using
different radio-tracers (injection of 20 mCi, 20 min capture time): (A)
99mTc-sestamibi imaging at 2 h post-injection, (B)
99mTc-DTPA-Caelyx at
2 h post-injection, (C)
99mTc-DTPA at 1 h post-injection and (D)
99mTc-
DTPA at 2 h post-injection.
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